News and information on generic drugs sold in retail pharmacies, as well as their suppliers.
Pfizer plans to launch Humira biosimilar in 2023.
Public quality standards set forth by USP increased competition in the generic medicines market and reduced overall prescription drug costs by $11 billion in 2015 and 2016.
Fresenius Kabi's generic Emend provides clinicians with a treatment alternative that has a 24-month shelf life.
Tarceva and its generics had a market value of approximately $145 million during the year ended Sept, 30, 2019.
Eli Kalif will join Teva as executive vice president and chief financial officer on Dec. 22.
Epiduo gel had a market value of about $33.7 million for the 12 month period ended September 2019, according to IQVIA.
Teva and Celltrion's Truxima is the first biosimilar to Genentech’s Rituxan (rituximab).
Fresenius Kabi is expanding its heparin and Simplist prefilled syringe portfolio with the addition of a small-volume presentation of Heparin.
With the FDA approval of Ziextenzo — a biosimilar of Neulasta — Sandoz is the first and only company to offer long- and short-acting filgrastim biosimilar treatment options.
Generic Bentyl is Camber's first injectable product to hit the market.
Paul Campanelli has been named Endo chairman of the board, and will continue as president and CEO until a successor is appointed.
Lupin's levothyroxine sodium tablets now is approved as a generic of Synthroid, Unithroid, and Levoxyl.
Lidocaine has a market value of about $60 million.
Carbidopa tablets had a market value of roughly $7.7 million for the 12 months ending August 2019, according to IQVIA.